RxDoctor Payments Data

Darrell McBride, DO

Infectious Disease · Danville, PANPI 1508127069

Payments from drug & device makers

$19,429in general payments, 2019–2025

Across 54 payments — averaging $359.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$19K
  • AstraZeneca$58
  • Pfizer$55
  • Ferring Pharmaceuticals Inc.$54

What the payments were for

  • Consulting fees$1,3907%
  • Speaking & faculty fees$13,51070%
  • Travel & lodging$2,88215%
  • Food & beverage$1,6478%

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead51$19,263
AstraZeneca1$58
Pfizer1$55
Ferring Pharmaceuticals Inc.1$54

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,429 in reported general payments places this provider in the 85th percentile of 457 infectious disease providers in Pennsylvania.

See all infectious disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$39,610
Medicare patients
238
Services billed
414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala217$896,552
TivicayDolutegravir Sodium115$307,836
PrezcobixDarunavir/Cobicistat64$151,577
GenvoyaElviteg/Cob/Emtri/Tenof Alafen29$129,538
DescovyEmtricitabine/Tenofov Alafenam53$112,322
RukobiaFostemsavir Tromethamine13$110,010
OdefseyEmtricitab/Rilpiviri/Tenof Ala23$84,475
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf16$72,161
TriumeqAbacavir/Dolutegravir/Lamivudi14$50,697
JulucaDolutegravir/Rilpivirine13$43,772
CompleraEmtricita/Rilpivirine/Tenof Df12$41,822
Etravirine26$25,735
IsentressRaltegravir Potassium12$23,575
PifeltroDoravirine13$21,519
Darunavir23$8,659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$19,263$1,138,412299 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 457 infectious disease providers in Pennsylvania.

Other infectious disease in Danville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →